Inventor · disambiguated record
Sangeeta Ray
Also filed as: RAY SANGEETA · RAY SANGEETA BANERJEE
26 granted patents·24 pending applications·125 citations·filing 2008–2024
95Inventor score
Files withUNIV JOHNS HOPKINS46ADVANCED ACCELERATOR APPLICATIONS ITALY SRL1CHANDRAN SACHIN S1POMPER MARTIN1The Johns Hopkins Universt1
Top patents by PatentIndex Score
50 records- 0197US9694091B2Labeled inhibitors of prostate specific membrane antigen (PSMA) biological evaluation, and use of imaging agentsUNIV JOHNS HOPKINS·Filed 2015·Granted Jul 4, 2017·19 cites·19 claims
- 0296US11661402B2PSMA-targeting compounds and uses thereofUNIV JOHNS HOPKINS·Filed 2022·Granted May 30, 2023·3 cites·19 claims
- 0396US11021450B2PSMA targeted fluorescent agents for image guided surgeryUNIV JOHNS HOPKINS·Filed 2020·Granted Jun 1, 2021·4 cites·21 claims
- 0496US9776977B2PSMA-targeting compounds and uses thereofUNIV JOHNS HOPKINS·Filed 2014·Granted Oct 3, 2017·14 cites·7 claims
- 0595US10039845B2Labeled inhibitors of prostate specific membrane antigen (PSMA) biological evaluation, and use of imaging agentsUNIV JOHNS HOPKINS·Filed 2017·Granted Aug 7, 2018·7 cites·18 claims
- 0692US10736974B2Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapyUNIV JOHNS HOPKINS·Filed 2015·Granted Aug 11, 2020·4 cites·1 claims
- 0792US10717750B268Ga-labeled NOTA-chelated PSMA-targeted imaging and therapeutic agentsUNIV JOHNS HOPKINS·Filed 2016·Granted Jul 21, 2020·4 cites·12 claims
- 0891US10683272B2Metal/radiometal-labeled PSMA inhibitors for PSMA-targeted imaging and radiotherapyUNIV JOHNS HOPKINS·Filed 2015·Granted Jun 16, 2020·5 cites·20 claims
- 0990US9884132B2Homomultivalent and heteromultivalent inhibitors of prostate specific membrane antigen (PSMA) and uses thereofUNIV JOHNS HOPKINS·Filed 2016·Granted Feb 6, 2018·9 cites·13 claims
- 1089US10688198B2Salicylic acid-based polymeric CEST contrast agents targeting prostate-specific membrane antigen and uses thereofUNIV JOHNS HOPKINS·Filed 2016·Granted Jun 23, 2020·4 cites·40 claims
- 1189US10653806B2Homomultivalent and heteromultivalent inhibitors of prostate specific membrane antigen (PSMA) and uses thereofUNIV JOHNS HOPKINS·Filed 2018·Granted May 19, 2020·4 cites·8 claims
- 1288US9371360B2Homomultivalent and heteromultivalent inhibitors of prostate specific membrane antigen (PSMA) and uses thereofUNIV JOHNS HOPKINS·Filed 2012·Granted Jun 21, 2016·12 cites·5 claims
- 1387US11813340B2PSMA targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapyUNIV JOHNS HOPKINS·Filed 2019·Granted Nov 14, 2023·2 cites·31 claims
- 1487US9422234B2Prostate specific membrane antigen (PSMA) targeted nanoparticles for therapy of prostate cancerCHANDRAN SACHIN S·Filed 2008·Granted Aug 23, 2016·14 cites·26 claims
- 1585US10369113B2Prostate specific membrane antigen (PSMA) targeted nanoparticles for therapy of prostate cancerUNIV JOHNS HOPKINS·Filed 2016·Granted Aug 6, 2019·4 cites·19 claims
- 1684US2025230135A1Metal/radiometal-labeled psma inhibitors for psma-targeted imaging and radiotherapyUNIV JOHNS HOPKINS·Filed 2024·Application pending·0 cites
- 1783US2025195700A1Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancerUNIV JOHNS HOPKINS·Filed 2024·Application pending·0 cites
- 1882US11458213B2Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancerUNIV JOHNS HOPKINS·Filed 2017·Granted Oct 4, 2022·1 cites·14 claims
- 1981US11478558B2Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancerUNIV JOHNS HOPKINS·Filed 2018·Granted Oct 25, 2022·1 cites·12 claims
- 2081US10029023B2Theranostic imaging agents and methods of usePOMPER MARTIN·Filed 2012·Granted Jul 24, 2018·10 cites·13 claims
- 2179US2023348405A1Psma-targeting compounds and uses thereofUNIV JOHNS HOPKINS·Filed 2022·Application pending·0 cites
- 2278US12233137B1PSMA targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapyUNIV JOHNS HOPKINS·Filed 2023·Granted Feb 25, 2025·0 cites·20 claims
- 2377US2025177580A1Psma targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapyUNIV JOHNS HOPKINS·Filed 2024·Application pending·0 cites
- 2475US12065413B2PSMA targeted fluorescent agents for image guided surgeryUNIV JOHNS HOPKINS·Filed 2021·Granted Aug 20, 2024·0 cites·19 claims
- 2575US2024140971A1Psma targeted radiohalogenated ureas for cancer radiotherapyUNIV JOHNS HOPKINS·Filed 2023·Application pending·0 cites
- 2675US2023015736A1Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancerUNIV JOHNS HOPKINS·Filed 2022·Application pending·0 cites
- 2774US2022135529A1Metal/radiometal-labeled psma inhibitors for psma-targeted imaging and radiotherapyUNIV JOHNS HOPKINS·Filed 2022·Application pending·0 cites
- 2874US2024150323A1Psma targeted fluorescent agents for image guided surgeryUNIV JOHNS HOPKINS·Filed 2023·Application pending·0 cites
- 2970US2020109124A1Psma targeted fluorescent agents for image guided surgeryThe Johns Hopkins Universt·Filed 2019·Application pending·0 cites
- 3069US10188754B2Compositions and methods for chemical exchange saturation transfer (CEST) based magnetic resonance imaging (MRI)UNIV JOHNS HOPKINS·Filed 2014·Granted Jan 29, 2019·4 cites·13 claims
- 3167US11911488B2Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapyUNIV JOHNS HOPKINS·Filed 2020·Granted Feb 27, 2024·0 cites·4 claims
- 3267US2020290982A1Metal/radiometal-labeled psma inhibitors for psma-targeted imaging and radiotherapyUNIV JOHNS HOPKINS·Filed 2020·Application pending·0 cites
- 3365US11814365B2PSMA targeted fluorescent agents for image guided surgeryUNIV JOHNS HOPKINS·Filed 2018·Granted Nov 14, 2023·0 cites·36 claims
- 3463US2023147035A1Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancerUNIV JOHNS HOPKINS·Filed 2022·Application pending·0 cites
- 3562US2018009767A9Psma targeted fluorescent agents for image guided surgeryUNIV JOHNS HOPKINS·Filed 2017·Application pending·0 cites
- 3661US2021040126A168Ga-LABELED NOTA-CHELATED PSMA-TARGETED IMAGING AND THERAPEUTIC AGENTSUNIV JOHNS HOPKINS·Filed 2020·Application pending·0 cites
- 3760US2020330613A1Salicylic acid-based polymeric cest contrast agents targeting prostate-specific membrane antigen and uses thereofUNIV JOHNS HOPKINS·Filed 2020·Application pending·0 cites
- 3857US11078166B2Triazole conjugated ureas, thioureas, carbamates, and reversed carbamates for PSMA-targeted imaging agents and uses thereofUNIV JOHNS HOPKINS·Filed 2016·Granted Aug 3, 2021·0 cites·1 claims
- 3955US2022401592A1Low molecular weight and polyamidoamine (pamam) dendrimer based psma-specific dual contrast agents for optical and photoacoustic imaging and theranostic agents for treating prostate cancerUNIV JOHNS HOPKINS·Filed 2022·Application pending·0 cites
- 4053US11871895B2Raman spectroscopy reporters and methods for molecular imaging of tissue in vivoUNIV JOHNS HOPKINS·Filed 2016·Granted Jan 16, 2024·0 cites·21 claims
- 4153US2021338846A1Competitive prostate-specific membrane antigen (psma) binding agents for reduction of non-target organ uptake of radiolabeled psma inhibitors for psma positive tumor imaging and radiopharmaceutical therapyUNIV JOHNS HOPKINS·Filed 2019·Application pending·0 cites
- 4252US2020170960A1Prostate specific membrane antigen (psma) targeted nanoparticles for therapy of prostate cancerUNIV JOHNS HOPKINS·Filed 2019·Application pending·0 cites
- 4351US2022054659A1Psma-targeted pamam dendrimers for specific delivery of imaging, contrast and therapeutic agentsUNIV JOHNS HOPKINS·Filed 2019·Application pending·0 cites
- 4450US2023226227A1Prostate specific membrane antigen (psma) ligands and uses thereofADVANCED ACCELERATOR APPLICATIONS ITALY SRL·Filed 2020·Application pending·0 cites
- 4547US2016075667A1Compositions and methods for chemical exchange saturation transfer (cest) magnetic resonance imaging (mri)UNIV JOHNS HOPKINS·Filed 2014·Application pending·0 cites
- 4646US2021308286A1Long-circulating psma-targeted phototheranostic agentUNIV JOHNS HOPKINS·Filed 2019·Application pending·0 cites
- 4745US2024382629A1Heterobivalent and homobivalent agents targeting fibroblast activation protein alpha and/or prostate-specific membrane antigenUNIV JOHNS HOPKINS·Filed 2022·Application pending·0 cites
- 4845US2020231614A1Psma targeted radiohalogenated ureas for cancer radiotherapyUNIV JOHNS HOPKINS·Filed 2016·Application pending·0 cites
- 4938US2019192699A1Nuclear imaging and radiotherapeutics agents targeting carbonic anhydrase ix and uses thereofUNIV JOHNS HOPKINS·Filed 2017·Application pending·0 cites
- 5037US10857246B2Nuclear imaging and radiotherapeutics agents targeting carbonic anhydrase IX and uses thereofUNIV JOHNS HOPKINS·Filed 2016·Granted Dec 8, 2020·0 cites·27 claims
Join the waitlist — get patent alerts
Get an alert when Sangeeta Ray files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →